Public Research Library
Specialties:
Most Popular Reports:
- Laser Body Sculpting SmartLipo-Trends in Use
- Essure Permanent Birth Control
- Oral Contraceptives Market Evaluation
- Trends and Forecast of Dental Implant Cases
- Avastin and the AVADO Trial Survey
Newest Reports:
Hereditary Angioedema: Treatment Awareness
A Survey of Fifty Allergists
Study Description
|
Topic |
Hereditary Angioedema Treatments |
|
Respondent Type |
Physicians |
|
Specialties Covered |
Allergists |
|
Region |
United States Only |
|
Methodology |
Online survey, self-administered via a Panel Intelligence website Duration: 15 minutes Size: 50 respondents Fielding Dates: November 9 to November 10, 2007 |
Objectives
Evaluate treatments in development for hereditary angioedema (HAE)
§ Determine current prevalence of HAE patients and HAE attacks in the United States
§ Identify physician awareness of treatments in development for HAE
§ Examine the factors that drive allergists to prescribe medications for HAE
§ Evaluate each treatment on a number of factors including:
· Onset of action
· Duration of effect
· Ease of administration
· Side effect profile
§ Gain insight into the scenarios in which physicians would use each HAE treatment
§ Anticipate the impact of reimbursement on uptake of the treatments
Companies and Products Mentioned in This Report
|
Company |
Ticker Symbol |
Product(s) |
|
Jerini |
JI4.DE |
Icatibant |
|
Dyax |
DYAX |
DX-88 |
|
Pharming Grp NV |
Rhucin | |
|
Lev Pharmaceuticals |
LEVP.OB |
Cinryze |
|
CSL Behring |
CSL |
Berinert-P |
Inclusion Criteria and Respondent Demographics
|
Inclusion Criteria
|
§ Board-certified or eligible allergists § In practice between 2 and 30 years § Spends at least 75% of professional time in clinical practice § Treated at least 1 HAE patient in the last 12 months |
Reports become free one year after the publication date.
 about us contact us |
 |
| © Panel Intelligence, LLC. 1999-2008. All rights reserved. A wholly owned subsidiary of MCF Corporation (NASDAQ: MERR) Privacy Policy |